Publications by authors named "P O Rivas"

Salicylic acid (SA) is a bioregulator well-known for mitigating salinity damage in plants. However, no studies have examined the interaction between SA and salinity in , a species rich in bioactive molecules. Therefore, we aimed to evaluate the effect of SA application on under different salinity levels.

View Article and Find Full Text PDF

Fingolimod is a sphingosine-1-phosphate receptor modulator used to treat multiple sclerosis. While fingolimod has been associated with an increased risk of cryptococcal meningitis, its correlation with other deep mycoses remains unclear. In this study, we conducted a scoping review of fingolimod associated with histoplasmosis, based on a case report, a literature review, and data from the FDA Adverse Events Reporting System (FAERS) as of January 24th, 2023.

View Article and Find Full Text PDF

In this study we have identified POLθ-S6K-p62 as a novel druggable regulator of radiation response in prostate cancer. Despite significant advances in delivery, radiotherapy continues to negatively affect treatment outcomes and quality of life due to resistance and late toxic effects to the surrounding normal tissues such as bladder and rectum. It is essential to develop new and effective strategies to achieve better control of tumor.

View Article and Find Full Text PDF

Background: Despite maternal flavivirus infections' linkage to severe maternal and fetal outcomes, surveillance during pregnancy remains limited globally. Further complicating maternal screening for these potentially teratogenic pathogens is the overwhelming subclinical nature of acute infection. This study aimed to understand perinatal and neonatal risk for poor health outcomes associated with flaviviral infection during pregnancy in El Salvador.

View Article and Find Full Text PDF
Article Synopsis
  • This study looks at the safety of giving oral treatment to adult patients diagnosed with bacteremia after they leave the emergency department.
  • It involved 206 patients with fever, comparing those with low-risk bacteremia who received oral treatment to similar non-bacteremic patients.
  • Results showed that both groups had similar and low rates of 14-day mortality and unplanned medical visits, indicating that early oral treatment for low-risk bacteremia is safe.
View Article and Find Full Text PDF